We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Examining Product Risk in Context: The Case of Zomepirac-Reply

Thomas P. Gibson, MD
JAMA. 1994;272(16):1252-1253. doi:10.1001/jama.1994.03520160036028.
Text Size: A A A
Published online


In Reply.  —Dr Spielberg suggests that the company's "Dear Doctor" letter of April 9, 1982, describing reports of anaphylactic reactions to zomepirac was inadequate because it stated that those reactions were similar to those reported in association with the use of other nonsteroidal anti-inflammatory drugs.After the marketing of zomepirac in 1980, reports of adverse experiences resembling anaphylactic reactions were reported to Ortho-McNeil Pharmaceutical. A number of those reports occurred in aspirin-sensitive patients for whom zomepirac and other nonsteroidal anti-inflammatory drugs are contraindicated. These were promptly reported to the FDA. In close collaboration with the FDA, the company drafted and issued the Dear Doctor letter to draw attention to these reactions and provide additional information to physicians so that zomepirac could be properly prescribed.Advertising campaigns with appropriate fair balance have always been acceptable forms of promotion for approved and marketed medications. However, because of continued reports of anaphylactic reactions,


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.